Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-Based Cohort
Clin Oncol (R Coll Radiol) 2021 Jul 02;[EPub Ahead of Print], D Ksienski, PT Truong, ES Wai, NS Croteau, A Chan, T Patterson, M Clarkson, S Hackett, S Irons, M LesperanceFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.